An observational study in Multiple Sclerosis, sponsored by Region Gävleborg. Not yet recruiting at 1 site in Sweden. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-08.
Sponsored by Region Gävleborg · Observational
Among 91 studies in Multiple Sclerosis with a site in Sweden — 10 open to participants now, 19 under way, 6 of them phase 3. Multiple Sclerosis · Sweden.
Among the 91 studies in Multiple Sclerosis with a site in Sweden, this one is the 12th largest by planned enrollment of the 16 observational ones, is one of 4 that started in 2026, is one of 16 observational ones, reaches primary completion later than 6 of the 18 other live ones, and was the 85th registered.
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's planned enrollment of 75 is below the median of 100 across 970 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →10 of the 91 studies in Multiple Sclerosis with a site in Sweden are open now, in 12 countries. Each count lists the studies.
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →91 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2026.
Median enrollment 278 across the 75 interventional studies, 179 across the 16 observational. Of the 70 that completed or were terminated, 41 (59%) have results posted.
63 of 91 have an industry lead sponsor. The 10 most frequent:
Region Gävleborg is the lead sponsor of 14 studies on the registry; 4 are open to participants now.
Region Gävleborg has 2 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Multiple Sclerosis with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03477500Phase 3Haukeland University HospitalRandomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) | 2026-11-21 |
| NCT07211516Region GävleborgRelationship Between Cognition, Workforce Participation and Well-Being in Individuals With Multiple Sclerosis | 2026-11 |
| NCT07131553Karolinska InstitutetEvaluation of the Wheelchair School (Drivkraft) a Clinical Study | 2027-02-01 |
| NCT05901259Otto Bock Healthcare Products GmbHThe EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes | 2027-08-01 |
| NCT07149662Region StockholmImmune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy | 2027-10 |
Among the 91 studies in Multiple Sclerosis with a site in Sweden, from their registry updates:
Multiple sclerosis (MS) is a chronic neurodegenerative disease and a leading cause of reduced workforce participation due to neurological illness in Western countries. Over the past 30 years, new treatments have reduced symptom burden, allowing patients to stay in the workforce longer. However, fatigue and cognitive impairments remain major barriers to work capacity. This project aims to examine factors important for work ability and well-being in persons with MS and cognitive impairments. The specific research questions are:
The findings from the study aim to enhance work-oriented rehabilitation and provide a deeper understanding of how to support individuals with MS in maintaining employment and overall well-being
Patients of working age with MS in Region Gävleborg who have performed a neuropsychological assessment during the 5 years prior to study start and who are not suffering from other diagnosis which impact their work ability to a large extent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Multiple sclerosis Age between 18-65 Performed a neuropsychological assessment at the Neurology department at Gävle Hospital during the last 5 years (counting from study start) -
Exclusion Criteria:
Other diagnosis hindering work participation more than MS
-
Time of neuropsychological assessment from 5 years before until study start.
Work participation
Percentage of full-time work. 100 % full-time work and 0% is not working at all.
Time frame: Baseline
Hospital anxiety and depression scale (HADS)
Self-assessment of anxiety and depression. Consists of two scales measuring the probability of having anxiety and depression respectively. Min score 0, max 21 for each scale. Higher scores indicate higher probability of anxiety/depression.
Time frame: Baseline
WHO-5 Well-Being Index
Overall rating of well-being. The WHO-5 score range is a raw score of 0-25, which is then multiplied by 4 to get a percentage score of 0-100. Higher score indicates higher well-being.
Time frame: Baseline
Brief index of job satisfaction (BIAJS)
The Brief Index of Affective Job Satisfaction (BIAJS) has a score range of 1 to 5 for each of its four items, based on a 5-point Likert scale where 1 is "strongly disagree" and 5 is "strongly agree". The total BIAJS score is the sum of these four items, resulting in a possible range from 4 to 20, with higher scores indicating greater affective job satisfaction.
Time frame: Baseline
Work-life balance
Questions from the subscale "Quantitative demands" of the Copenhagen Psychosocial Questionnaire (COPSOQ-III) related to the demands of work. The COPSOQ-III uses Likert-like scales, and its items are coded with values of 0, 25, 50, 75, and 100 to achieve a 0-100 scale. Higher scores indicate more demands.
Time frame: Baseline
Can-Work-S
Three questions from a questionnaire developed to measure work-life balance after cancer. Each item ranges from 1 to 5 with higher scores indicating worse work-life balance.
Time frame: Baseline
Plan to share: No — To comply with the conditions set by the ethical review board, individual participant data (IPD) cannot be shared with other researchers. However, aggregated data are available upon reasonable reques
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Nov 2026, 7 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Region Gävleborg